CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024 16:05 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and
Provides Business Update
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
November 08, 2024 16:23 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia
ARTIDIS announces publication demonstrating the nanomechanical signature of response to low-dose radiotherapy followed by CAR T cell therapy in solid tumors.
November 08, 2024 08:00 ET
|
Artidis AG
BASEL, Nov. 8, 2024 — ARTIDIS, a clinical-stage health technology company developing the first clinically integrated nanomechanical platform for tissue analytics, today announced a peer-reviewed...
CARGO Therapeutics to Participate in Upcoming Investor Conferences
November 05, 2024 16:05 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Participate in Upcoming Investor Conferences
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
November 05, 2024 09:30 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for...
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity
November 05, 2024 09:23 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
November 05, 2024 09:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Outpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 05, 2024 09:00 ET
|
Outpace Bio
Outpace Bio at SITC 2024: AI-powered OPB-101 CAR T cells show lasting functional persistence, enhanced anti-tumor activity, & stem central memory phenotype
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
November 04, 2024 16:30 ET
|
Cellectis Inc.
UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs – one...
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
October 28, 2024 17:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024